Clinical trials · Connecticut
Neuroblastoma clinical trials in Connecticut
We’re tracking 9 recruiting neuroblastoma studies with a site in Connecticut — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Connecticut
- NCT06831552Recruiting
Supporting families of children with high-risk neuroblastoma
This study tests a resource intervention to help families with low income who have a child with high-risk neuroblastoma. It aims to reduce financial stress and improve care during treatment.
Hartford, ConnecticutAges Up to 17 years - NCT06465199RecruitingPhase 1/Phase 2
Eflornithine and AMXT 1501 for Advanced Childhood Cancers
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Hartford, ConnecticutAges Up to 26 years - NCT05489887RecruitingPhase 2
Naxitamab with frontline chemotherapy for high-risk neuroblastoma
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
Hartford, ConnecticutAges 1–21 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hartford, ConnecticutAges Up to 30 years - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hartford, ConnecticutAges 12 months–30 years - NCT06540963RecruitingPhase 2
Tipifarnib and naxitamab for relapsed or refractory neuroblastoma
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Hartford, ConnecticutAges 1–21 - NCT02559778RecruitingPhase 2
Precision treatment trial for children with advanced neuroblastoma
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
Hartford, ConnecticutAges Up to 22 years - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
New Haven, ConnecticutAges 6 months–25 years - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Hartford, ConnecticutAges Up to 30 years
Neuroblastoma trials by city in Connecticut
Where these studies are running in Connecticut
Institutions with a site for the recruiting neuroblastoma studies listed above.
- Connecticut Children's Medical Center · 8 studies
- Yale University · 2 studies
- Yale New Haven Hospital
What taking part in a neuroblastoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Neuroblastoma trials in other states
Common questions
- Are there neuroblastoma clinical trials in Connecticut?
- Yes. We're currently tracking 9 recruiting neuroblastoma studies with a site in Connecticut, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neuroblastoma study in Connecticut?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Connecticut to take part?
- Not necessarily. These studies have a site in Connecticut, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neuroblastoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neuroblastoma studies open in Connecticut regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.